AKR1B1 / Aldo-keto reductase family 1 member B1 · IHC design guide

Design Immunohistochemistry for AKR1B1

Plan paraffin-section AKR1B1 staining using the catalog antibody’s IHC conditions (datasheet PB10035). Use adrenal zona fasciculata cells as a positive reference (HPA tissue IHC), then assess staining against the cytoplasmic expectation (UniProt).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for AKR1B1 (IHC for AKR1B1): expected localisation Cytoplasm expected; adrenal compartment unreported (UniProt; HPA tissue IHC), antibody PB10035, validated IHC image, and IHC protocol steps — Printable **AKR1B1** IHC protocol sheet — expected localisation Cytoplasm expected; adrenal compartment unreported (UniProt; HPA tissue IHC), antibody PB10035, controls and protocol steps. Open the full AKR1B1 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

AKR1B1 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasm expected; adrenal compartment unreported (UniProt; HPA tissue IHC)
	Staining pattern	High zona fasciculata staining; subcellular pattern unreported (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6 HIER, heat-mediated (datasheet PB10035)
	Positive control ⓘ	Adrenal gland+4 more · see all
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections (standard IHC practice; not target-specific); target-specific effects are unknown.
	Caveat	Expression varies sharply by tissue and cell type (HPA tissue IHC)
	Regulation	Osmotic stress response in embryonic epithelial cells (UniProt)
	Isoform / epitope	0 annotated isoforms; no signal peptide or propeptide (UniProt)

Section 1

Recommended AKR1B1 IHC & IF Protocols

The catalog antibody uses citrate pH 6 retrieval (datasheet PB10035). The published IHC protocols below cover human endometrial and ovarian, porcine reproductive, and canine mammary tissues (cited PMC articles).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded rat intestine tissues; fixative not specified (datasheet PB10035)
Fixation	Image fixative and duration unreported (datasheet PB10035); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Citrate pH 6, 20 min (datasheet PB10035)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet PB10035)
Primary antibody	Rabbit anti-AKR1B1, 0.5-1μg/ml (datasheet PB10035)
Primary incubation	Overnight at 4 °C (datasheet PB10035)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB10035)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	AKR1B1-positive staining in cells in zona fasciculata of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Distinct expression in adrenal gland. No signal in the no-primary control.

💡Decision noteStart with citrate pH 6 heat retrieval for the catalog antibody (datasheet PB10035); use each article’s stated retrieval conditions when reproducing its protocol (cited PMC articles).

Section 2

What Is the Expected AKR1B1 Staining Pattern?

AKR1B1 is a cytoplasmic protein with no transmembrane segment (UniProt P15121: subcellular location and topology). In paraffin-section IHC, expect strongest staining in adrenal zona fasciculata cells (HPA: High); Purkinje cells, cytotrophoblasts, seminal-vesicle glandular cells, skin basal-layer cells and spermatogonia show medium staining (HPA: Medium). HPA rates the tissue IHC profile Enhanced, reflecting high consistency between antibody staining and RNA expression (HPA: reliability).

What am I looking at on my slide?
Strong cytoplasmic staining in adrenal zona fasciculata cells, with discernible cell boundaries.	This fits the strongest supplied positive tissue pattern (HPA: High in zona fasciculata) and the expected cytoplasmic location (UniProt P15121: Cytoplasm). Score the relevant cells rather than treating every adrenal cell as an expected positive (HPA: cell-specific tissue profile).
Predominantly nuclear, sharply membranous or extracellular staining in most cells.	Reassess specificity because cytoplasm is the expected IHC compartment (UniProt P15121: Cytoplasm; no transmembrane segment). A membrane-associated description is reported specifically for Purkinje cells (HPA: Purkinje cells, cytoplasm/membrane); supported nucleoplasmic localization comes from ICC-IF, not tissue IHC (HPA: subcellular).
Strong signal in an HPA-negative cell population, such as adipocytes or bone-marrow hematopoietic cells.	This conflicts with the reported cell-specific IHC profile (HPA: Not detected in those cells). Consider antibody cross-reactivity or endogenous chromogenic activity as possibilities; the appearance alone cannot distinguish them (general IHC practice). Check matched controls before interpreting it as AKR1B1.
Uniform haze across tissue, including cell-free areas or the negative control.	Treat this as background until controls establish a cell-specific signal (general IHC practice). Check blocking, washes, antibody concentration and detection reagents; diffuse color by itself does not reproduce the HPA cell-specific pattern (HPA: tissue IHC profile).
No staining in adrenal zona fasciculata cells.	A blank result misses the strongest supplied positive population (HPA: High in zona fasciculata). First check tissue preservation, antibody and detection controls, and the retrieval conditions specified for the chosen assay (general IHC practice); absence of color alone does not establish absent AKR1B1.

💡Expected AKR1B1 appearanceCall an IHC result positive when adrenal zona fasciculata cells show clear, relatively strong cytoplasmic signal (HPA: High; UniProt P15121: Cytoplasm); indiscriminate color in HPA-negative cells or across the section warrants a background or specificity check (HPA: tissue profile; general IHC practice).

How each factor affects the staining
Which tissue provides the clearest positive comparison?	Adrenal zona fasciculata cells are High, whereas the other listed positive cell populations are Medium (HPA: tissue IHC). Compare the intended cell population, not whole-section color, because the supplied levels are cell-specific (HPA: tissue profile).
What does antibody validation establish?	HPA reports Enhanced tissue IHC reliability and lists four antibodies with Enhanced IHC status (HPA: reliability; antibody validation). This supports the reported pattern but does not validate a different antibody, dilution or laboratory workflow (general IHC interpretation).
Does topology predict surface staining?	No transmembrane segment is annotated, and UniProt places AKR1B1 in the cytoplasm (UniProt P15121: topology and location). A predominantly cell-surface IHC pattern therefore needs a specificity check; the reported Purkinje-cell cytoplasm/membrane pattern is a tissue-specific observation (HPA: cerebellum).
Where should IF/ICC signal appear?	Mainly in cytosol, with additional supported nucleoplasmic localization (HPA: subcellular ICC-IF). That observation can inform compartment interpretation, but it is distinct from the paraffin-section IHC tissue pattern (HPA: subcellular and tissue IHC).
What can be inferred about retrieval or fixation sensitivity?	The supplied UniProt and HPA records do not establish an AKR1B1-specific fixation effect or retrieval condition. Follow the selected IHC assay's instructions and assess retrieval with appropriate controls (general IHC practice); do not infer sensitivity from topology or HPA staining levels.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
The adrenal positive control is blank.	The result conflicts with High zona fasciculata staining (HPA: adrenal gland); an assay failure or unsuitable section is possible (general IHC practice).	Confirm the relevant cells are present, then check antibody preparation, retrieval, detection reagents and a working assay control (general IHC practice).
Nuclei dominate the chromogenic signal.	The compartment differs from UniProt's cytoplasmic location (UniProt P15121: Cytoplasm); ICC-IF reports additional nucleoplasm, which does not by itself validate nuclear-dominant tissue IHC (HPA: subcellular).	Compare cytoplasmic signal in the adrenal positive control and repeat with appropriate negative and antibody-specific controls (HPA: High in zona fasciculata; general IHC practice).
Adipocytes stain as strongly as zona fasciculata cells.	HPA reports adipocytes as Not detected and zona fasciculata cells as High (HPA: tissue IHC); cross-reactivity or nonspecific detection is possible (general IHC practice).	Check the cell identities and run primary-omission and detection controls; compare the staining pattern with another validated antibody where available (general IHC practice; HPA: Enhanced IHC antibody entries).
Color develops without primary antibody.	The signal cannot be attributed to primary-antibody binding; endogenous enzyme activity or detection chemistry may contribute (general chromogenic IHC practice).	Check the detection reagents and apply the assay's endogenous-activity blocking procedure, then repeat the control (general chromogenic IHC practice).
The whole section has a weak brown haze.	Diffuse color obscures the cell-specific profile reported by HPA (HPA: tissue IHC); nonspecific binding or incomplete washing is possible (general IHC practice).	Inspect the negative control, then adjust blocking, washing or antibody concentration within the chosen assay's guidance (general IHC practice).
A medium-level tissue appears negative while the adrenal control stains.	HPA reports Medium staining in specific cells of cerebellum, placenta, seminal vesicle, skin and testis, versus High in adrenal zona fasciculata (HPA: tissue IHC).	Verify that the relevant cell type is present, examine it at comparable detection settings and record the cell-specific result; avoid calling the entire tissue negative from other unstained cells (HPA: tissue profile; general IHC practice).

Source: UniProt P15121 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing AKR1B1 staining

IHC analysis of AKR1B1 using anti-AKR1B1 antibody (PB10035). AKR1B1 was detected in paraffin-embedded section of rat intestine tissues. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-AKR1B1 Antibody (PB10035) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PB10035 · IHCIHC analysis of AKR1B1 using anti-AKR1B1 antibody (PB10035). AKR1B1 was detected in paraffin-embedded section of rat intestine tissues. Heat

IHC analysis of AKR1B1 using anti-AKR1B1 antibody (PB10035). AKR1B1 was detected in paraffin-embedded section of rat adrenal gland tissues. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-AKR1B1 Antibody (PB10035) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PB10035 · IHCIHC analysis of AKR1B1 using anti-AKR1B1 antibody (PB10035). AKR1B1 was detected in paraffin-embedded section of rat adrenal gland tissues.

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000085662-AKR1B1/tissue/cerebral+cortex#imid_20017553

HPA · Adrenal glandHuman Protein Atlas IHC, Adrenal gland. Source: https://www.proteinatlas.org/ENSG00000085662-AKR1B1/tissue/adrenal+gland#imid_247

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000085662-AKR1B1/tissue/colon#imid_20019479

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000085662-AKR1B1/tissue/liver#imid_20019480

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA026425; green = AKR1B1, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for AKR1B1 IHC & IF

🧪Run adrenal gland first: zona fasciculata cells should stain strongly (HPA: High in cells in zona fasciculata). Use adipose tissue adipocytes as the biological negative (HPA: Not detected in adipocytes); on the adrenal slide, only cells independently confirmed to lack AKR1B1 should be treated as internal negatives and should show background-level signal.

Positive control tissue: Adrenal gland (Cells in zona fasciculata, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show AKR1B1 in A-431, U-251MG, U2OS, with annotated localisation: Cytosol (supported) (HPA subcellular).

Technical controls: Include no-primary (secondary-only) and rabbit IgG isotype controls, matching the primary antibody’s clonality if known, plus an AKR1B1 knockout control or peptide block if the immunizing peptide is available (caption: rabbit primary; standard IHC practice). Check endogenous peroxidase and biotin background in adrenal sections because the selected protocol uses biotin-based detection and DAB (caption: biotinylated secondary, SABC and DAB).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected PB10035 paraffin-section caption does not state its fixative (caption: fixative unreported). The demonstrated IHC procedure uses citrate retrieval at pH 6 for 20 minutes, but the evidence does not establish whether retrieval is essential (caption: heat-mediated retrieval); frozen-section performance is unreported, while ICC-IF images exist for A-431, U-251MG and U2OS without establishing that tissue IF is easier (HPA: subcellular images). In adrenal tissue, endogenous peroxidase or biotin may add background to the selected chromogenic detection method (caption: biotinylated secondary, SABC and DAB; standard IHC practice).

HPA tissue IHC evidence for AKR1B1

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Cells in zona fasciculata	High	Protein (IHC)	HPA →
Cerebellum	Purkinje cells - cytoplasm/membrane	Medium	Protein (IHC)	HPA →
Placenta	Cytotrophoblasts	Medium	Protein (IHC)	HPA →
Seminal vesicle	Glandular cells	Medium	Protein (IHC)	HPA →
Skin	Cells in basal layer	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Appendix	Glandular cells	Not detected	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	Not detected	Protein (IHC)	HPA →

Section 3

Advanced AKR1B1 IHC Tips

Troubleshoot AKR1B1 staining in paraffin sections by checking retrieval, cell identity, subcellular pattern and controls before comparing signal intensity.

Where should I start if AKR1B1 staining is weak in paraffin sections?

Start with heat-mediated retrieval in citrate buffer at pH 6 (datasheet PB10035). The catalog antibody stained a paraffin-embedded rat intestine section after 20 minutes of this retrieval, followed by 1 μg/ml primary antibody overnight at 4°C (datasheet PB10035). If signal remains weak, check that heating, cooling and section adhesion are consistent before changing retrieval conditions. Run any alternative buffer or heating time beside the starting condition, since an apparent gain may also increase background or damage morphology. Keep detection and exposure to chromogen matched across sections so the retrieval comparison is interpretable.

Could fixation explain weak or uneven AKR1B1 staining?

Target-specific sensitivity to fixation is unknown: the catalog image describes a paraffin-embedded section but does not state its fixative (datasheet PB10035). Record the fixative, fixation duration and tissue thickness for each specimen, then compare similarly processed sections before attributing a difference to AKR1B1 expression. Excessive or uneven fixation can alter epitope accessibility in routine IHC, so assess morphology and staining across the full section. Start troubleshooting with citrate retrieval at pH 6 under the documented conditions (datasheet PB10035). If fixation histories differ, include a common reference section in each run and interpret intensity comparisons cautiously.

What staining pattern is plausible for AKR1B1?

Expect a predominantly cytoplasmic pattern: UniProt places AKR1B1 in the cytoplasm, while HPA supports a main cytosolic location and an additional nucleoplasmic location (UniProt P15121; HPA subcellular). Its record lists no transmembrane segment, so a sharply exclusive cell-surface rim warrants scrutiny (UniProt P15121 topology). In adrenal gland, assess the cells in zona fasciculata, where HPA reports high staining (HPA: High in cells in zona fasciculata). Compare compartment patterns with a negative control and with neighboring cells on the same section. Faint nuclear signal alone should not override a discordant cell distribution or strong background when calling a section positive.

How should epitope uncertainty affect interpretation of variable staining?

The supplied UniProt record lists 0 isoforms for AKR1B1, so do not assign distinct staining patterns to annotated isoforms (UniProt P15121 isoforms). It lists acetylation and phosphorylation sites, including positions 2, 3, 95, 222 and 263, but the antibody epitope is not supplied (UniProt P15121 modified residues; datasheet PB10035). Consequently, a change in staining cannot establish that a modification blocked antibody binding. Compare serial sections with matched retrieval and detection, and examine whether the difference tracks cell type or processing. If epitope dependence matters, seek epitope information or test an independently characterized antibody before making that claim.

How can I assess AKR1B1 by multiplex IF alongside chromogenic IHC?

Use a separately validated marker for the expected cell population; for adrenal sections, assess cells in zona fasciculata, where HPA reports high AKR1B1 staining (HPA: High in cells in zona fasciculata). Choose well-separated fluorophores and favor a far-red channel if tissue autofluorescence obscures shorter wavelengths. Permeabilise sufficiently to reach a cytosolic epitope, since AKR1B1 is mainly cytosolic and has no annotated transmembrane segment (HPA subcellular; UniProt P15121 topology). Include single-stain and no-primary controls to assess spectral spillover and background. Treat any IF result as an independently optimized assay; the selected catalog image documents chromogenic IHC in a paraffin section (datasheet PB10035).

What should I check when DAB background obscures AKR1B1?

First compare a no-primary section with the stained section to locate signal arising from detection reagents or tissue. Apply a peroxidase block before chromogenic detection and inspect whether residual color follows vessels, damaged areas or section edges. The catalog image used a biotinylated secondary, an avidin–biotin complex and DAB, so consider a biotin block or an alternative detection chemistry if that workflow produces diffuse staining (datasheet PB10035). It also used 10% goat serum for blocking and 1 μg/ml primary antibody overnight at 4°C (datasheet PB10035). Adjust blocking, washing or primary concentration one variable at a time while retaining a reference section.

How should I score AKR1B1 staining across specimens? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and compartment before scoring; HPA reports high staining in adrenal zona fasciculata cells and mainly cytosolic localisation (HPA tissue IHC; HPA subcellular). For chromogenic IHC, record the percentage of viable target cells at each intensity and calculate an H-score from 0–300, or report percentage positive using a prespecified threshold. Normalize positive counts to total eligible cells, or positive area to viable tissue area, rather than whole-slide area. Exclude folds, necrosis and section edges by the same rules in every specimen. Keep retrieval, DAB development and imaging settings matched, and score controls alongside samples.

How can I distinguish genuine AKR1B1 staining from an artefact?

A convincing result follows the expected cells and compartment: HPA reports high staining in adrenal zona fasciculata cells, and AKR1B1 is mainly cytosolic (HPA tissue IHC; HPA subcellular). Compare that pattern with a no-primary control and inspect whether color clusters at cut edges, folds or necrotic regions. A dominant membrane rim is difficult to reconcile with the lack of an annotated transmembrane segment (UniProt P15121 topology). Check whether residual endogenous peroxidase contributes to DAB signal, particularly if color persists in the no-primary control. Interpret weak staining against processing-matched sections; HPA lists adipocytes as not detected, which is a reference pattern rather than proof of antibody specificity (HPA: Not detected in adipocytes).

Boster reagents

Best AKR1B1 / Aldo-keto reductase family 1 member B1 IHC Antibodies

PB10035 has real paraffin-section IHC images from rat intestine, rat adrenal gland, and human placenta (PB10035 image captions). No IF/ICC validation is supplied (catalog applications; IF images).

Real IHC data

Anti-AKR1B1 Antibody ®

Cat # PB10035

View product →

PB10035 is listed for IHC and has staining images from paraffin sections of rat intestine, rat adrenal gland, and human placenta (catalog applications; PB10035 image captions). Its stated reactivity is Human, Mouse, and Rat, while the IHC images show Human and Rat samples (catalog reactivity; PB10035 image captions).

Which to pick: Choose PB10035 for paraffin-section tissue IHC; its own captions report citrate retrieval at pH 6, 1 μg/ml primary antibody overnight, and DAB detection (PB10035 image captions). For IF/ICC, choose an IF-validated reagent: PB10035 has no listed IF/ICC application, dilution, or image; its host is Rabbit and its clone is unreported (catalog applications, IF dilution, IF images, host, clone). For cross-species work, PB10035 lists Human, Mouse, and Rat reactivity, but its captioned IHC evidence covers Human and Rat only; the fixative is unreported (catalog reactivity; PB10035 image captions).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry P15121 (ALDR_HUMAN, Aldo-keto reductase family 1 member B1).
Human Protein Atlas. AKR1B1 tissue IHC expression (reliability: Enhanced).
Human Protein Atlas. AKR1B1 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the nucleoplasm..
Human Protein Atlas. AKR1B1 antibody validation summary (4 antibodies).
AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas. Cancers 2021 — PMC8305663.
Aldose Reductase B1 in Pig Seminal Plasma: Identification, Localization in Reproductive Tissues, and Relationship With Quality and Sperm Preservation. Frontiers in cell and developmental biology 2021 — PMC8217816.
AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer. Cancers 2022 — PMC8834204.
AKR1B1 promotes canine mammary tumorigenesis via activation of PI3K/AKT signaling and acts as a serum biomarker. Scientific reports 2026 — PMC13346787.
PubMed PMID:2498333 — UniProt-cited evidence.
PubMed PMID:2504709 — UniProt-cited evidence.
PubMed PMID:2510130 — UniProt-cited evidence.